Why the Anatara (ASX:ANR) share price is rocketing 19% today

The Anatara Lifesciences Ltd (ASX: ANR) share price is one of the best performers on the ASX today. Here's what the company announced.

| More on:
investor looking excited at rising fortescue share price on laptop

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Anatara Lifesciences Ltd (ASX: ANR) share price is one of the best performers on the ASX today. This comes after the company announced it has secured an Australian patent for its animal health product, Detach and provided an update on its piglet challenge study.

At the time of writing, the life sciences company's shares are swapping hands for 21.5 cents, up 19.4%.

New patent grant

Anatara shares are pushing higher after investors appear pleased with the company's latest progress.

According to its release, Anatara advised it has been granted a patent to add to its portfolio. Approved by IP Australia, the patent will seek to protect Anatara's intellectual property, and provide a pathway for future commercialisation.

The new patent is titled, 'Anti-diarrhea formulation which avoids antimicrobial resistance' (patent number AU2019204496).

Anatara stated that its product, Detach uses the patent as a non-antibiotic solution to assist in controlling diarrheal disease. The patent covers using bromelain, an extract from pineapple stems, as a way to treat and prevent diarrhea caused by pathogenic microbes. However, the company noted that the new formulation does not kill pathogenic microbes.

The AU2019204496 patent is wholly-owned by Anatara, and is set to expire on 24 August 2038.

Anatara CEO, Steven Lydeamore commented:

The granting of the patent secures our intellectual property position and is a significant milestone towards commercialising our Detach animal health product. Scour in piglets is an expensive, debilitating and in some cases, life-threatening condition, and having a product that is registered for use in Australia, we are well placed to leverage our patent as we work towards a commercial deal.

Piglet challenge study commences

In further news boosting Anatara shares, the company revealed that its BONIFF-SMEC (bromelain-based formulation) (semi-moist extruded creep) study has begun. The project aims to test the formulated feed additive on piglets under an enterotoxigenic E. coli model. Anatara will closely evaluate the efficacy of the modified additive on piglet health, welfare, and performance after weaning.

The study is being conducted in partnership with Ridley Corporation, and is expected to be completed in June 2021.

Lydeamore commented:

Having focused our efforts on research and development over a number of years, we have developed a strong animal health pipeline and I look forward to providing the market with an update on the commercial significance of both the pig and poultry challenge trials in the coming months.

Anatara share price review

Over the past 12 months, the Anatara share price has gained over 20%, with year-to-date jumping 26%. The company's shares reached a 52-week high of 28 cents during the middle of last year, before treading lower.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Male hands holding Australian dollar banknotes, symbolising dividends.
Share Market News

BlueScope returns $438m to shareholders with special dividend

BlueScope will return $438 million to shareholders via a $1 per share special dividend after selling major assets.

Read more »

Man looking happy and excited as he looks at his mobile phone.
Broker Notes

Want silver exposure? Morgans says this ASX silver stock is a buy

The broker thinks this could be a high-risk, high-reward option for investors.

Read more »

CEO of a company talking.
Share Market News

Deep Yellow welcomes new CEO as part of ongoing uranium growth strategy

Deep Yellow has set a start date for new CEO Greg Field, with project development remaining on track as part…

Read more »

A young man goes over his finances and investment portfolio at home.
Broker Notes

What is Bell Potter saying about this high-flying ASX 200 share after its 140% rise?

Bell Potter has been looking at the metal detector manufacturer's performance this financial year.

Read more »

Cheerful businessman with a mining hat on the table sitting back with his arms behind his head while looking at his laptop's screen.
Share Market News

Monadelphous secures $300m Rio Tinto contract

Monadelphous secures a $300 million Rio Tinto contract, strengthening its maintenance services position in Australia’s resources sector.

Read more »

a uranium-fuelled mushroom shaped cloud explosion surrounded by a circle of rainbow light with a symbol of an atom to one side of it.
Opinions

What's next for the best-performing ASX 200 stock of 2025?

This ASX stock boomed in 2026.

Read more »

Woman thinking in a supermarket.
Dividend Investing

I'd buy this ASX dividend stock in any market

This business is a great option for dividends.

Read more »

Two kids are selling big ideas from a lemonade stand on the side of the road for cheap!
Share Market News

After crashing 8% yesterday, should investors buy the dip on these ASX 200 stocks?

These stocks could be a bargain today.

Read more »